SARS-CoV-2 uses major endothelial integrin αvβ3 to cause vascular dysregulation in-vitro during COVID-19.
Issue Date
2021-06-23Keywords
COVID-19CORONAVIRUS
cardiovascular complications
Metadata
Show full item recordJournal
PloS oneDOI
10.1371/journal.pone.0253347PubMed ID
34161337Item Type
ArticleLanguage
enEISSN
1932-6203ae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0253347
Scopus Count
Collections
Related articles
- Molecular Cross-Talk between Integrins and Cadherins Leads to a Loss of Vascular Barrier Integrity during SARS-CoV-2 Infection.
- Authors: Nader D, Kerrigan SW
- Issue date: 2022 Apr 25
- Biological and Clinical Consequences of Integrin Binding via a Rogue RGD Motif in the SARS CoV-2 Spike Protein.
- Authors: Makowski L, Olson-Sidford W, W-Weisel J
- Issue date: 2021 Jan 20
- The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells.
- Authors: Alghisi GC, Ponsonnet L, Rüegg C
- Issue date: 2009
- Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration.
- Authors: Yang Q, Hughes TA, Kelkar A, Yu X, Cheng K, Park S, Huang WC, Lovell JF, Neelamegham S
- Issue date: 2020 Oct 26
- SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity.
- Authors: Huang SW, Wang SF
- Issue date: 2021 Mar 17